Innovation and the research of original drug molecules have been key elements in the Company’s strategy since its foundation in 1901. With more than 1,200 employees in the field of research and development Richter today is the most significant pharmaceutical research base in the Central and Eastern European region
The Richter Group spent HUF 48.9 billion on research and development in 2019, which amounts to 9.6 per cent of its consolidated sales revenue.

Drug research and development entails four strategic directions: recombinant biotechnological activities, research and development of new chemical entities, late stage women’s healthcare projects and generic products.